Drug Design Methodologies
Developing advanced software for efficient, cost-effective, and risk-free structure-based drug design in pharma and biotech.
Founded
1998Developing advanced software for efficient, cost-effective, and risk-free structure-based drug design in pharma and biotech.
Founded with the mission to revolutionize drug discovery, Drug Design Methodologies develops cutting-edge computational software for structure-based drug design. Their core vision is to streamline and enhance the drug development process by chemically optimizing and accurately measuring drug-target binding. The company's innovative software identifies promising drug candidates and eliminates compounds with potential off-target effects, thereby accelerating and de-risking pharmaceutical and biotechnology pipelines while reducing costs.
Notable affiliations include partnerships with leading pharmaceutical companies and biotech firms. The company has achieved significant milestones, including the successful integration of their software into several high-profile drug development projects. By reducing the time and financial investment required for drug discovery, Drug Design Methodologies has made a substantial impact on the industry, facilitating the development of safer and more effective therapeutic solutions.
Companies similar to Drug Design Methodologies include PathDrugomics, QuantumBio, Schrödinger and Design Pharmaceuticals.
Drug Design Methodologies was founded in 1998.
Drug Design Methodologies' headquarters is located in St. Louis, MO, US.
Drug Design Methodologies' most recent funding round was for $50k (USD) in November 2017.
As of Nov 4, 2017, Drug Design Methodologies has disclosed funding of $50k (USD). Undisclosed round amounts are excluded.
Drug Design Methodologies has 2 employees as of Feb 4, 2024.
Design Pharmaceuticals
